attach research report excerpt
research report written
entir broker partner auerbach
grayson auerbach grayson
auerbach grayson distributing/provid
research report consider
upgrad buy rate lift price target
larg valuat chang attribut valu compani
success connect care strategi deliv three benefit
chang way think termin valu structur chang deliv
us market share replic jurisdict signific increas
instal base compliant patient coupl autom resuppli
solut drive durabl profit product cycl mask
rang final connect care also promot broader consolid hme
report normal dilut non- ep
higher model upsid driven larg part sustain market
share gain notabl mask product cycl prove
durabl previou cycl reflect larg shift us flow gener instal
base follow three year flow gener market share gain
platform connect care drive sporad out-performance market ex-
us sale surpris rais quarterli dividend
us fund outlook stabl medicar expect leav price structur
unchang earli strong us mask growth split equal market
share gain new patient despit new competitor product launch adopt
resm solut autom product resuppli patient on-going benefit
japan franc reimburs favor connect devic
near term ep chang longer term forecast reflect ep upgrad
ebitda margin benefit sg effici
target price base dcf impli
ep ev reflect ebitda per share uplift
valuat compris three element increas termin growth assumpt
 oper margin expans fx
translat valuat
upgrad buy rate lift price target
larg valuat chang attribut valu
compani success connect care strategi deliv
three benefit chang way think termin valu
structur chang deliv us market share replic
jurisdict signific increas instal base
compliant patient coupl autom resuppli solut
drive durabl profit product cycl mask
rang final connect care also promot broader consolid
hme distribut channel yield on-going sg effici
ep higher model upsid
driven larg part sustain market share gain notabl mask
product cycl prove durabl previou cycl
reflect larg shift us flow gener instal base follow
three year flow gener market share gain platform
connect care drive sporad out-performance market ex-u
sale surpris rais quarterli dividend
webcast takeaway us fund outlook stabl medicar expect
leav price structur unchang earli strong us mask
growth split equal market share gain new patient despit new
competitor product launch adopt solut
autom product resuppli patient on-going benefit japan
franc reimburs favour connect devic jurisdict
forecast near term ep chang longer term forecast reflect
ep upgrad ebitda margin benefit sg effici
valuat target price base dcf
impli ep ev reflect ebitda
per share uplift valuat compris three element
increas termin growth assumpt
oper margin expans fx translat valuat
risk catalyst
risk advers reimburs cut sleep apnoea fund product
launch competitor litig includ patent infring suit
develop indic outsid sleep apnoea
share issu
issu wilson advisori stockbrok limit abn australian financi servic licenc particip asx group
read conjunct disclosur disclaim report import disclosur regard compani subject report explan
recommend found end document
health equip suppli
profit loss
fund equiti
fund debt
fund cash
health equip suppli
inc result
tabl summari result pcp estim
point result
us sale still suggest share gain us flow gener sale
ahead forecast perform well comp mask grew
 low comp suggest share gain increas resuppli activ manag
said resuppli aspect assist hme custom base still quit under-
penetr technolog brought caretouch jaysec acquisit improv
econom promot resuppli consum patient mask
accessori channel consolid oper pursu opportun
cloud-bas solut
profit scale autom
personalis patient prompt complianc valid insur reimburs
support product sourc bill ship averag utilis mask us still
like lower per patient per year gradual improv
ab varamerica flow mask flow mask gross expenses- nmamortis n/apre-tax tax rate net non-gaap net expens guidancerevenuegross august
health equip suppli
row result reflect usual jurisdict lumpi mask impress
favour reimburs chang japan franc continu flow although
french compon like complet row flow gener sale
reflect market growth mask grew constant currenc versu
comp optimist european countri develop
enact reimburs polici favour connect devic understand pilot
studi underway germani assess potenti health econom benefit
gross margin expens guidanc gross margin
slightli estim given stronger expect contribut us
sale mix manag guid gross margin guidanc
sg better expect manag say would see slightli higher
trend toward expens expect
net sale
balanc sheet cash flow report net debt re-
financ recent compani enter new unsecur syndic facil
provid five-year revolv credit facil five-year term loan
oper cash flow ahead forecast account lower net
work capit movement forecast growth oper cash next year
tabl longer term forecast detail follow result
 america row- medic devic pcp devic group gross amortis incom net incom pre-tax net non-gaap net dilut non-gaap dilut oper cash gross august
health equip suppli
figur equiti asset unlev beta
wilson estim base weekli return
model calcul price target per
share us common stock import chang input
model provid explicit free cash flow forecast
treat year termin year estim resm
weight averag cost capit note rank
among lowest beta stock australian healthcar per
share valuat compar last time reflect three
lift termin growth assumpt
reflect durabl competit advantag connect care
contribut busi perman structur
chang us market inevit translat
major healthcar market although contrast driven
health econom factor longer success mask
product cycl pronounc earn leverag
alreadi evid tg upgrad account
valuat upgrad refer point use
tg competitor fph
increas free cash flow forecast period
assess sg continu come percentag
net revenu last decad sg improv
net sale improv long
term forecast contribut valuat upgrad
fx translat chang aud assumpt
contribut valuat chang
betaequ capital-expenditure work pv termin dcf forecast period growth risk debt us long run oper featur sleep apneapv fcff revenu ot gross sg net net debt net basic dilut stock tp us /share us common tp august
health equip suppli
revis target price per share impli ep ev
figur ev/ebitda time seri target price consist current multipl
assess reason valuat plot forward excess cash
return differ compani wacc versu ev/invest capit
resm excess look expens basi excess return
figur valuat appear reason basi excess cash return
health equip suppli
resm inc develop manufactur sell posit air pressur pap devic treatment sleep disord breath recent
year compani diversifi pap offer market oral applianc ventil form respiratori support
upgrad buy rate lift price target larg valuat chang attribut valu
compani success connect care strategi deliv three benefit chang way think termin valu
structur chang deliv us market share replic jurisdict signific increas instal base
compliant patient coupl autom resuppli solut drive durabl profit product cycl mask
rang final connect care also promot broader consolid hme distribut channel yield on-going sg effici
grow easier access diagnosi sleep disord
rel short product cycl refresh price point
new devic area
gross margin expos fx aud sgd vs usd
 sg typic net sale
product mix higher-end apap ventil bilevel mask
higher gross margin
competit intensifi low-end cpap market
net debt averag
leverag
restor sustain industri us devic volum flow
increment margin benefit mix shift apap
risk view
increas competit price point
slower-than-expect market growth particularli challeng
price reimburs challeng usa elsewher
relat poor complianc cpap
health equip suppli
disclaim disclosur
